Discovery of compounds that reactivate p53 mutants in vitro and in vivo is a research paper published in Cell chemical biology (2022). On theSindex it has a DataRank of 0. It has been cited 30 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Science Foundation
Grant: CHE060073N
National Institutes of Health
Grant: DOD BC140911
National Institutes of Health
Grant: P30CA062203
National Institutes of Health
Grant: R01CA11256
National Institutes of Health
Grant: R01GM132826
National Institutes of Health
Grant: UL1 TR0001414
NINDS NIH HHS
Grant: R21 NS063874
NCATS NIH HHS
Grant: UL1 TR001414
NCI NIH HHS
Grant: R01 CA112560
NCI NIH HHS
Grant: R21 CA267495
National Institutes of Health
Grant: 5R01GM132826-03
A MULTISCALE APPROACH TO TARGET THE ACHILLES HEEL OF P53 CANCER MUTANTS
National Institutes of Health
Grant: 5T32GM140911-02
G-RISE at Old Dominion University
National Institutes of Health
Grant: 3UL1TR001414-06S1
THE SEARCH FOR COVID-19 PREVENTION AND CURE: ADDRESSING THE CRITICAL ROLE OF INNATE/ADAPTIVE IMMUNITY BY INTEGRATING NOVEL INFORMATICS, TRANSLATIONAL TECHNOLOGIES, AND ONGOING CLINICAL TRIAL RESEARCH
National Institutes of Health
Grant: 3P30CA062203-27S1
Clinical Trial Advancement and Development for Sarcomas
DOD
University of California
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Cancer therapeutics via small molecule-mediated p53 mutant reactivation